Rolny Peter, Vatn Morten
Division for Gastroenterology/Hepatology, Department of Medicine, Sahlgrenska University Hospital/Östra, Göteborg, Sweden.
Scand J Gastroenterol. 2013 Feb;48(2):131-5. doi: 10.3109/00365521.2012.733954. Epub 2012 Oct 30.
Corticosteroids are the mainstay of therapy for severe ulcerative colitis. However, at least a third of patients fail to respond and face a colectomy. In these, rescue therapy with cyclosporine or infliximab (IFX), aimed at avoiding surgery, has been used in recent years. Of the two options, infliximab is largely preferred in both Sweden and Norway, whereas cyclosporine (CyA) is generally regarded as difficult to use, rather toxic and showing limited long-term efficacy. In light of some new recent data, herein, we provide an update of the literature in the field. It appears that there are theoretical and practical arguments on each side, and as of today, the choice between IFX or CyA for rescue therapy cannot be made on strong evidence. Thus, the best choice of medical rescue therapy will depend on the results of ongoing RCTs as well as future research in the field.
皮质类固醇是重症溃疡性结肠炎治疗的主要手段。然而,至少三分之一的患者对此无反应并面临结肠切除术。近年来,针对这些患者,已采用环孢素或英夫利昔单抗(IFX)进行挽救治疗,旨在避免手术。在这两种选择中,瑞典和挪威大多更倾向于使用英夫利昔单抗,而环孢素(CyA)通常被认为难以使用、毒性较大且长期疗效有限。鉴于近期的一些新数据,在此我们提供该领域文献的最新情况。似乎双方都有理论和实际的论据,截至目前,基于有力证据无法在IFX和CyA之间做出用于挽救治疗的选择。因此,最佳的药物挽救治疗选择将取决于正在进行的随机对照试验的结果以及该领域未来的研究。